PARP1 and lip and oral cavity carcinoma: In addition to these reports, we recently reported that a clinical PARP1 inhibitor, olaparib, has synergetic effects with cisplatin in vitro and enhances its suppressive effects against the growth of tumor xenografts in vivo [24], suggesting that PARP inhibitors could be favorable for oral cancer therapy in combination with conventional chemotherapy.